ClinicalTrials.gg
CompletedNCT01152996Updated May 28, 2014Results posted

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by Takeda. Completed. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2014-05-28.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,075
Allocation
Not applicable
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
2nd of 54
1,075 · median 413
Started
2010
with 5 others
Phase 3
31 of 54
1 open now
Registered
12th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 2nd largest by enrollment, is one of 6 that started in 2010, is one of 31 in phase 3, and was the 12th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.

Read the detailed description

Depression has been recognized as a chronic illness that imposes a significant burden on individuals, families and society. Major depressive disorder (MDD) is among the most important causes of disability worldwide, in both developing and developed countries. Major depressive disorder is reported to be the most common mood disorder, with a lifetime prevalence of about 15% and as high as 25% in women. Major depressive disorder is characterized by the presence of 1 or more major depressive episodes that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration.

This is a multicenter extension study designed to allow eligible patients who have completed short-term efficacy and safety studies LuAA21004_315 (NCT01153009), LuAA21004_316 (NCT01163266) and LuAA21004_317 (NCT01179516) to receive the 52-week treatment with vortioxetine in this open-label extension study. Participants are expected to return to the site for approximately 13 visits.

A safety follow-up call will be made 4 weeks after completion of the 52-week treatment period.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Depression
  • Melancholia
  • Paraphrenia
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed either study LuAA21004_315 ( NCT01153009), LuAA21004_316 (NCT01163266), or LuAA21004_317 (NCT01179516) immediately prior to enrollment in the extension study (ie, the baseline visit is the same visit as the Week 8 [Lu AA21004_317] or Week 10 [Lu AA21004_315 or Lu AA21004_316] assessment of the preceding protocol).
  • Suffers from a recurrent major depressive episode) as the primary diagnosis according to , Fourth Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.3x) at entry into the prior study.
  • Twelve-month continuation treatment with Lu AA21004 is indicated for the treatment of this participant according to the opinion of the investigator.
  • Females of who are sexually active with a nonsterilized male partner agree to routinely use adequate throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Has Major Depressive Disorder for whom other psychiatric disorders (mania, bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed during the prior study.
  • In the investigator's clinical judgment, has a significant risk of suicide and/or a score of ≥5 points on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale (MADRS).
  • In the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  • Has a moderate or severe ongoing adverse event related to study medication from the prior study.
  • Has used/uses disallowed concomitant medication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,075 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.

    Drug: Vortioxetine

Interventions

  • Vortioxetine tablets

    Also known as: LuAA21004

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%

    Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.

    Time frame: Over the 52 week period

  2. Number of Participants With Serious Treatment-Emergent Adverse Events

    Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.

    Time frame: Over the 52 week period

  3. Treatment-Emergent Adverse Events Leading to Study Discontinuation

    Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.

    Time frame: Over the 52 week period

Secondary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52

  2. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.

    Time frame: Baseline and Weeks 4, 24, and 52

  3. Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

    The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.

    Time frame: Baseline and Weeks 4, 24, and 52

  4. Change From Baseline in Sheehan Disability Scale (SDS) Total Score

    The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.

    Time frame: Baseline and Weeks 12, 24, 36, and 52

  5. Change From Baseline in SDS Work/School Subscale

    The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

    Time frame: Baseline and Weeks 12, 24, 36, and 52

  6. Change From Baseline in SDS Social Life Subscale

    The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

    Time frame: Baseline and Weeks 12, 24, 36, and 52

  7. Change From Baseline in SDS Family Life/Home Responsibilities Subscale

    The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

    Time frame: Baseline and Weeks 12, 24, 36, and 52

07

Results

Posted May 28, 2014

Participant flow

Participants took part in the study at 143 investigative sites in the United States from 07 Sep 2010 to 31 May 2013.

Participant flow — Overall Study
MilestoneVortioxetine
Started1075
Treated1073
Completed538
Not completed537
Withdrew: Withdrawal by subject142
Withdrew: Adverse event115
Withdrew: Lost to follow-up112
Withdrew: Lack of efficacy68
Withdrew: Noncompliance41
Withdrew: Other36
Withdrew: Protocol violation22
Withdrew: Elevated liver enzymes1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%

Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.

Time frame:
Over the 52 week period
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%
participantsVortioxetine
Nausea258
Diarrhea80
Vomiting68
Constipation65
Nasopharyngitis68
Viral upper respiratory tract infection66
Upper respiratory tract infection60
Weight increased65
Headache136
Insomnia56
PrimaryNumber of Participants With Serious Treatment-Emergent Adverse Events

Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.

Time frame:
Over the 52 week period
Reported as:
Number · participants
Number of Participants With Serious Treatment-Emergent Adverse Events
participantsVortioxetine
Number of Participants With Serious Treatment-Emergent Adverse Events29
PrimaryTreatment-Emergent Adverse Events Leading to Study Discontinuation

Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.

Time frame:
Over the 52 week period
Reported as:
Number · participants
Treatment-Emergent Adverse Events Leading to Study Discontinuation
participantsVortioxetine
Treatment-Emergent Adverse Events Leading to Study Discontinuation117
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
units on a scaleVortioxetine
Week 1 (n=1043)-2.7 ± 6.32
Week 2 (n=1043)-4.8 ± 7.50
Week 4 (n=1004)-6.1 ± 8.50
Week 8 (n=936)-7.9 ± 9.19
Week 12 (n=843)-8.5 ± 9.55
Week 16 (n=777)-9.1 ± 9.50
Week 20 (n=747)-9.4 ± 10.03
Week 24 (n=697)-9.7 ± 9.64
Week 28 (n=670)-9.5 ± 10.20
Week 36 (n=617)-9.7 ± 10.44
Week 44 (n=573)-10.3 ± 10.70
Week 52 (n=534)-10.3 ± 11.00
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.

Time frame:
Baseline and Weeks 4, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
units on a scaleVortioxetine
Week 4 (n=1029)-2.6 ± 4.98
Week 24 (n=742)-4.2 ± 5.84
Week 52 (n=548)-4.8 ± 6.52
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.

Time frame:
Baseline and Weeks 4, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
units on a scaleVortioxetine
Week 4 (n=1030)-0.6 ± 0.99
Week 24 (n=743)-1.0 ± 1.16
Week 52 (n=549)-1.2 ± 1.32
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score

The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.

Time frame:
Baseline and Weeks 12, 24, 36, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score
units on a scaleVortioxetine
Week 12 (n=650)-2.8 ± 6.69
Week 24 (n=494)-3.9 ± 6.88
Week 36 (n=414)-4.0 ± 7.37
Week 52 (n=381)-4.7 ± 7.11
SecondaryChange From Baseline in SDS Work/School Subscale

The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

Time frame:
Baseline and Weeks 12, 24, 36, and 52
Reported as:
Mean · units on a scale
Change From Baseline in SDS Work/School Subscale
units on a scaleVortioxetine
Week 12 (n=650)-0.8 ± 2.42
Week 24 (n=494)-1.2 ± 2.48
Week 36 (n=414)-1.2 ± 2.60
Week 52 (n=381)-1.4 ± 2.61
SecondaryChange From Baseline in SDS Social Life Subscale

The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

Time frame:
Baseline and Weeks 12, 24, 36, and 52
Reported as:
Mean · units on a scale
Change From Baseline in SDS Social Life Subscale
units on a scaleVortioxetine
Week 12 (n=942)-1.0 ± 2.53
Week 24 (n=721)-1.4 ± 2.55
Week 36 (n=617)-1.4 ± 2.82
Week 52 (n=545)-1.6 ± 2.85
SecondaryChange From Baseline in SDS Family Life/Home Responsibilities Subscale

The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.

Time frame:
Baseline and Weeks 12, 24, 36, and 52
Reported as:
Mean · units on a scale
Change From Baseline in SDS Family Life/Home Responsibilities Subscale
units on a scaleVortioxetine
Week 12 (n=942)-0.9 ± 2.39
Week 24 (n=721)-1.3 ± 2.47
Week 36 (n=617)-1.4 ± 2.74
Week 52 (n=545)-1.6 ± 2.76

Adverse events

Collected over 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—29/1,073 (2.7%)854/1,073 (79.6%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventVortioxetine
Suicide attemptPsychiatric disorders3/1073
Cholecystitis acuteHepatobiliary disorders2/1073
Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1073
Atrial fibrillationCardiac disorders1/1073
Abdominal painGastrointestinal disorders1/1073
Esophageal ruptureGastrointestinal disorders1/1073
CholecystitisHepatobiliary disorders1/1073
CholelithiasisHepatobiliary disorders1/1073
Anal abscessInfections and infestations1/1073
Latent syphilisInfections and infestations1/1073
Most frequent other events
Most frequent other events
EventVortioxetine
NauseaGastrointestinal disorders258/1073
HeadacheNervous system disorders136/1073
DiarrheaGastrointestinal disorders80/1073
VomitingGastrointestinal disorders68/1073
NasopharyngitisInfections and infestations68/1073
Viral upper respiratory tract infectionInfections and infestations66/1073
ConstipationGastrointestinal disorders65/1073
Weight increasedInvestigations65/1073
Upper respiratory tract infectionInfections and infestations60/1073
InsomniaNervous system disorders56/1073

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vortioxetine
Mean44.5 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine
Female790
Male285
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine
Caucasian (or White, including Hispanic)813
Black/African American249
Asian7
American Indian/Alaska Native5
Native Hawaiian/Other Pacific Islander1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vortioxetine
Hispanic or Latino104
Non-Hispanic and Non-Latino971
Weight
Weight(kg))Vortioxetine
Mean88.77 ± 24.160
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vortioxetine
Mean31.60 ± 8.061
Height
Height(cm)Vortioxetine
Mean167.44 ± 9.456
Montgomery Åsberg Depression Rating Scale (MADRS) total score
Montgomery Åsberg Depression Rating Scale (MADRS) total score(scores on a scale)Vortioxetine
Mean20.0 ± 10.70

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2010
First posted
Jun 29, 2010
Start
Sep 2010
Primary completionActual
May 2013
CompletionActual
May 2013
Results delay requested
Oct 8, 2013
Results first posted
May 28, 2014
Last update
May 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01152996
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 29, 2010
Start date
Sep 2010
Primary completion
May 2013
Completion
May 2013
Results posted
May 28, 2014
Last update
May 28, 2014

Study contacts

Senior Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion